Healthcare
Live Price
Offline$13.45
+1.13% today
1Y Change
+37.68%
Window
Jun 27, 2025 โ Jun 17, 2026
Coverage: 245 bars ยท Jun 27, 2025 โ Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Astellas Pharma Inc. (ALPMY) is a Healthcare stock with a market cap of $3.95T. The stock last traded around $13.45 and up 37.7% across the available one-year price window (Jun 27, 2025 โ Jun 17, 2026). Baseline metrics include revenue growth of +18.6%, EPS growth of +508.7%, a dividend yield of 3.5%. What stands out right now is revenue +18.6%, EPS +508.7%, free cash flow +293.1% with operating margin 18.9% and ROIC 12.1%. The dividend matters to the case here, with a current yield around 3.5%. Valuation is more restrained than many high-expectation growth names at P/E 13.6 and price/sales 1.8. Overall, the current profile looks closer to a income-oriented value setup than a generic broad-market placeholder. Stock Foundry combines ALPMY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+18.6% vs +7.6% peer median
Operating Margin
Near sector median
+18.9% vs +19.4% peer median
P/E
Below sector median
13.6 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 24, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +18.6% and EPS at +508.7%, with operating margin around 18.9%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 3.5%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +0.6% over the next 5 trading days and finished higher after 2 of those reports.
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 24, 2026 | โ | -2.1% | -9.5% | -7.9% |
2026 Feb 4, 2026 | +24.8% | +0.8% | +7.7% | -2.3% |
2025 Oct 30, 2025 | +50.5% | -4.2% | +3.4% | +15.1% |
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
ALPMY
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
ALPMY Max Drawdown
-21.28%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Uses the longest available daily history for ALPMY and SPY.
Company Overview
Astellas Pharma Inc.
Valuation, growth, profitability, and balance sheet signals.
Company announcements and filings-style updates.
Next Step
After the overview, the strongest next step is usually chart context or a tighter compare set.